As most on this forum would know, there is no short answer to...

As most on this forum would know, there is no short answer to this question and no definitive answer. There are many variables in the equation. Whether or not the the trials are afforded orphan drug status. The size of the trials in terms of how many subjects are required (sadly, this means women with quite often terminal cervical cancer, what outcomes the drug has stated its aiming for. Also whether or not the FDA sends PRR back to the drawing board to redo any trial stages if they are not happy with techniques or results etc. To a lesser extent now, funding may also play an important part in how long this thing takes to get to commercialisation. I don't think even Martin could give a definitive answer to be honest.